关于世界卫生组织广泛耐药结核病新定义的解读

doi:10.3969/j.issn.1000-6621.2021.06.003

中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (6): 539-541.doi: 10.3969/j.issn.1000-6621.2021.06.003

关于世界卫生组织广泛耐药结核病新定义的解读

李仁忠(), 阮云洲, 李玉红

102206 北京,中国疾病预防控制中心结核病预防控制中心耐药防治部

收稿日期:2021-04-09 出版日期:2021-06-10 发布日期:2021-06-02
通信作者: 李仁忠 E-mail:Lirz@chinacdc.cn
基金资助:
探索提高贫困地区肺结核发现水平项目(0525)

Interpretation of the new definition of extensive drug-resistant tuberculosis defined by World Health Organization

LI Ren-zhong(), RUAN Yun-zhou, LI Yu-hong

Department of Drug Resistant Tuberculosis Control, National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

Received:2021-04-09 Online:2021-06-10 Published:2021-06-02
Contact: LI Ren-zhong E-mail:Lirz@chinacdc.cn

摘要/Abstract

摘要：

目的世界卫生组织(World Health Organization,WHO)于 2006年首次提出的广泛耐药结核病(extensive drug-resistant tuberculosis,XDR-TB)定义对于指导耐药结核病的防控工作起到了重要的指导作用。随着新的诊断技术和药品的出现,WHO于2021年1月对原有的XDR-TB定义进行了更新。本文对XDR-TB新定义更新的背景和历史、理由,以及总体原则进行解读,并对XDR-TB新定义对我国今后结核病防治工作开展的影响及意义进行总结,以供我国结核病防治工作者借鉴和参考。

关键词: 泛耐药结核病, 概念形成, 规范

Abstract:

The definition of extensive drug-resistant tuberculosis (XDR-TB) first proposed by World Health Organization (WHO) in 2006 has played an important role in guiding the prevention and control of drug-resistant tuberculosis. With the development of new diagnostic technologies and new drugs, WHO updated the original definition of XDR-TB in January 2021. In this paper, the background, history, reasons and general principles of the new definition of XDR-TB were interpreted, and the impact and significance of the new definition for the tuberculosis control in the future were summarized, in order to provide reference for tuberculosis control workers in China.

Key words: Extensively drug-resistant tuberculosis, Concept formation, Benchmarking

李仁忠, 阮云洲, 李玉红. 关于世界卫生组织广泛耐药结核病新定义的解读[J]. 中国防痨杂志, 2021, 43(6): 539-541. doi: 10.3969/j.issn.1000-6621.2021.06.003

LI Ren-zhong, RUAN Yun-zhou, LI Yu-hong. Interpretation of the new definition of extensive drug-resistant tuberculosis defined by World Health Organization[J]. Chinese Journal of Antituberculosis, 2021, 43(6): 539-541. doi: 10.3969/j.issn.1000-6621.2021.06.003

参考文献 11

[1]	World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27-29 October 2020. Geneva: World Health Organization, 2021.
[2]	O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. London: Government of the United Kingdom, 2016.
[3]	Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis, 2007,13(3):380-387. doi: 10.3201/eid1303.061400. doi: 10.3201/eid1303.061400 URL
[4]	World Health Organization. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization, 1997.
[5]	World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2006.
[6]	World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016.
[7]	World Health Organization. WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update. Geneva: World Health Organization, 2018.
[8]	World Health Organization. WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2020.
[9]	World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance. Geneva: World Health Organization, 2016.
[10]	World Health Organization. WHO consolidated guidelines on tuberculosis. module 3: diagnosis: rapid diagnostics for tuberculosis detection. Geneva: World Health Organization, 2020.
[11]	中华人民共和国国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发中国结核病预防控制工作技术规范(2020年版)的通知. 国卫办疾控函〔2020〕279号. 2020-04-02.

[1]	段鸿飞, 陶勇. 《眼内结核诊断规范》团体标准解读[J]. 中国防痨杂志, 2025, 47(3): 258-261.
[2]	吴桂辉, 马瑶, 蔡阳, 梁丽, 邹莉萍. 含贝达喹啉方案治疗艾滋病合并原发广泛耐药肺结核患者一例[J]. 中国防痨杂志, 2022, 44(3): 299-302.
[3]	吴国兰, 高静韬, 陈晓红, 陈力舟, 翁丽珍, 郭志平, 陈秀平, 林剑东, 陈素霞, 高孟秋, 刘宇红. 含贝达喹啉方案治疗耐多药/广泛耐药结核病的近期疗效及安全性分析[J]. 中国防痨杂志, 2021, 43(9): 899-904.
[4]	陈秋奇, 邓国防. 浅议我国结核病共病及管理[J]. 中国防痨杂志, 2021, 43(6): 546-549.
[5]	时正雨, 吴桂辉, 黄涛, 刘宇红, 高孟秋, 陈蕾, 李曦, 杨铭, 何畏, 陈艳, 鲁小莉, 高静韬, 李亮. 含贝达喹啉方案治疗耐多药/广泛耐药结核病的24周单组观察性研究[J]. 中国防痨杂志, 2021, 43(5): 487-494.
[6]	田丹, 胡晓萌, 金武, 程长浩, 熊磊群, 胡荣华, 金倩, 柳云, 杜鹃. 含贝达喹啉方案治疗67例痰菌培养转阴的耐多药/广泛耐药肺结核患者单臂单中心临床观察[J]. 中国防痨杂志, 2021, 43(11): 1146-1152.
[7]	裴异, 高静韬, 黄云辉, 何芳, 封文军, 杨晓云, 胡羽萌, 雷丽萍, 施利. 含贝达喹啉方案治疗44例痰菌阳性耐多药/广泛耐药肺结核24周疗效分析[J]. 中国防痨杂志, 2021, 43(11): 1139-1145.
[8]	杨春龙, 周林, 陈明亭. 《病原学检测阴性肺结核诊断流程(T/CHATA 008—2020)》解读[J]. 中国防痨杂志, 2021, 43(11): 1116-1119.
[9]	成君. 《新生入学体检结核病检查规范》解读[J]. 中国防痨杂志, 2020, 42(9): 987-989.
[10]	沈鑫, 肖筱, 白丽琼, 潘启超. 《学校肺结核患者密切接触者筛查及处置规范》解读[J]. 中国防痨杂志, 2020, 42(9): 990-991.
[11]	张灿有, 夏辉, 成君. Ⅱ级生物安全柜在结核病实验室中的检测及报告要求[J]. 中国防痨杂志, 2020, 42(9): 903-909.
[12]	中国防痨协会骨结核专业分会. 新型冠状病毒肺炎疫情下骨关节结核外科的管理规范[J]. 中国防痨杂志, 2020, 42(3): 185-190.
[13]	孙明雷, 关黎, 赵娟, 王晨, 邹丹丹, 梁立波. 传染病防控视角下耐多药及广泛耐药结核病患者交通出行的立法思考[J]. 中国防痨杂志, 2020, 42(12): 1268-1271.
[14]	应若嫣, 黄晓辰, 王洁, 刘一典, 沙巍, 杨华. 耐药MTB分离株对不同组合抗结核药品体外药物敏感性试验的结果分析[J]. 中国防痨杂志, 2020, 42(11): 1183-1182.
[15]	徐彩红, 张慧, 刘剑君. 《从业人员健康体检规范——结核病部分》解读[J]. 中国防痨杂志, 2020, 42(10): 1134-1136.

关于世界卫生组织广泛耐药结核病新定义的解读

Interpretation of the new definition of extensive drug-resistant tuberculosis defined by World Health Organization

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 11

相关文章 15

编辑推荐

Metrics

本文评价